This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The purpose of this study is to evaluate the safety of taking T cells (lymphocytes, a type of white blood cell) from patients' blood with a brain tumor called malignant glioma, modifying the DNA of these cells in the laboratory to kill glioma cells, growing the modified cells in large numbers in the laboratory, and then re-administering the modified T cells directly into the brain. This study will also try to determine if the reprogrammed T cells attack glioma cells in the brain. It is anticipated that participation in this study will last approximately six months from the time of enrollment. After treatment on this study is over, subjects will continue to be followed indefinitely. Many patients with malignant glioma respond to treatment (show no evidenceof disease on standard clinical tests) but then relapse (the tumor starts to grow again). The major reason why patients have disease relapse is the ability of some tumor cells to survive chemotherapy and/or radiation therapy. Additional ways of killing tumor cells that may be resistant to chemotherapy and radiation therapy may improve the outcome of treatment. A type of immune cell called a cytotoxic T lymphocyte (CTL) can be engineered to kill glioma cells in the laboratory. This is done by inserting a piece of DNA into the T cells that allows them to recognize glioma cells. From a single T cell (clone), genetically-modified T cells can be grown to large numbers in the laboratory. The treatment to be used in this study has never been used before in animals or humans, and it is not known whether these clones will kill glioma cells when administered back to patients. Because the safety of this treatment in humans is also not known, the genetically-modified T cell clones have been engineered to also include a gene (called HyTK) that will allow the T cells to be killed with the antiviral drug ganciclovir if the clones are causing any serious side effects.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
General Clinical Research Centers Program (M01)
Project #
Application #
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Internal Medicine/Medicine
Schools of Medicine
Los Angeles
United States
Zip Code
Kelsey, Megan M; Braffett, Barbara H; Geffner, Mitchell E et al. (2018) Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. J Clin Endocrinol Metab 103:2309-2318
Davis, J N; Asigbee, F M; Markowitz, A K et al. (2018) Consumption of artificial sweetened beverages associated with adiposity and increasing HbA1c in Hispanic youth. Clin Obes 8:236-243
Kleinberger, Jeffrey W; Copeland, Kenneth C; Gandica, Rachelle G et al. (2018) Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med 20:583-590
Berkowitz, Robert I; Marcus, Marsha D; Anderson, Barbara J et al. (2018) Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. Pediatr Diabetes 19:191-198
Kriska, Andrea; El Ghormli, Laure; Copeland, Kenneth C et al. (2018) Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. Pediatr Diabetes 19:36-44
Venditti, E M; Tan, K; Chang, N et al. (2018) Barriers and strategies for oral medication adherence among children and adolescents with Type 2 diabetes. Diabetes Res Clin Pract 139:24-31
Detterich, Jon A (2018) Simple chronic transfusion therapy, a crucial therapeutic option for sickle cell disease, improves but does not normalize blood rheology: What should be our goals for transfusion therapy? Clin Hemorheol Microcirc 68:173-186
Gidding, Samuel S; Bacha, Fida; Bjornstad, Petter et al. (2018) Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study. J Pediatr 192:86-92.e5
Cooper, Aaron R; Lill, Georgia R; Shaw, Kit et al. (2017) Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients. Blood 129:2624-2635
Arslanian, Silva; El Ghormli, Laure; Bacha, Fida et al. (2017) Adiponectin, Insulin Sensitivity, ?-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY. Diabetes Care 40:85-93

Showing the most recent 10 out of 565 publications